Welcome to the e-CCO Library Archive!
P211
Anti-tumour necrosis factor drugs levels and correlation with short-term clinical remission in Crohn’s disease patients: results from the Predicrohn Study
M. Chaparro*1, I. Guerra2, M. Iborra3, J. L. Cabriada4, L. Bujanda5, C. Taxonera6, V. García-Sánchez7, I. Marín-Jiménez8, M. Barreiro-de Acosta9, I. Vera10, M. D. Martín-Arranz11, B. Hernández-Breijo12, F. Mesonero13, L. Sempere14, F. Gomollón15, J. Hinojosa16, F. Bermejo2, B. Beltrán3, I. Rodriguez-Lago4, J. M. Banales5, D. Olivares17, P. Aguilar-Melero7, L. Menchén8, R. Ferreiro9, I. Blazquez10, B. Benítez García11, L. Guijarro12, P. M. Linares1, M. Ramas1, J. P. Gisbert1
1Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 2Hospital Universitario de Fuenlabrada, Gastroenterology Unit, Madrid, Spain, 3Hospital Universitario La Fe and CIBERehd, Gastroenterology Unit, Valencia, Spain, 4Hospital Galdakao, Gastroenterology Unit, Vizcaya, Spain, 5Hospital de Donostia, Instituto Biodonostia, UPV/EHU and CIBEREHD, Gastroenterology Unit, Guipuzcoa, Spain, 6Hospital Clínico Universitario San Carlos and IdISSC, Gastroenterology Unit, Madrid, Spain, 7Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain, 8Hospital Gregorio Marañón and IiSGM, Gastroenterology Unit, Madrid, Spain, 9Hospital Clínico Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 10Hospital Universitario Puerta de Hierro, Gastroenterology Unit, Madrid, Spain, 11Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain, 12Universidad de Alcalá and CIBERehd, Systems Biology, Alcalá de Henares, Spain, 13Hospital Universitario Ramón y Cajal, Gastroenterology Unit, Madrid, Spain, 14Hospital General Universitario de Alicante, Gastroenterology Unit, Alicante, Spain, 15Hospital Clínico Universitario Lozano Blesa and CIBERehd, Gastroenterology Unit, Zaragoza, Spain, 16Hospital de Manises, Gastroenterology Unit, Valencia, Spain, 17Hospital Universitario Clínico San Carlos and IdISSC, Gastroenterology Unit, Madrid, Spain
P212
Inflammatory bowel disease patients seem to develop non-alcoholic steatohepatitis (NASH) independently from an altered metabolic profile or active bowel disease
A. Sartini*, M. Bianchini, S. Gitto, M. Di Girolamo, A. Bertani, A. Merighi, E. Villa
Gastroenterology Unit, Azienda Ospedaliero-Universitaria di Modena, Policlinico, Modena, Italy
P213
Predicting outcome of paediatric Crohn’s disease: role of clinical, endoscopic, and imaging findings at the diagnosis
M. Aloi*1, F. Civitelli1, S. Oliva1, E. Casciani2, G. D’Arcangelo1, A. Spatoliatore1, F. Viola1, S. Cucchiara1
1Sapienza University of Rome, Paediatric gastroenterology and liver Unit, Rome, Italy, 2Sapienza University of Rome, Radiology DEA, Rome, Italy
P214
Inflammatory bowel disease and endometriosis: is there a relationship?
M. Fortuna*1, A. Variola2, R. Montanari2, G. Ruffo3, P. Bocus4, A. Geccherle2
1Sacro Cuore Don Calabria Hospital, Multispecialistic Centre for Recto-Perineal Diseases (IBD Unit), Department of Gastroenterology, Negrar (Vr), Italy, 2Sacro Cuore Don Calabria Negrar Hospital, Multispecialistic Centre for Recto-Perineal Diseases (IBD Unit), Department of Gastroenterology, Negrar (VR), Italy, 3Sacro Cuore Don Calabria Negrar Hospital, Department of General Surgery, Negrar (VR), Italy, 4Sacro Cuore Don Calabria Negrar Hospital, Department of Gastroenterology - Endoscopy, Negrar (VR), Italy
P215
The influence of disease activity on birth outcomes in patients with inflammatory bowel disease: Meta- analysis
J. J. Park*1, H. J. Kim2, M.-A. Kim3
1Gangnam Severance Hospital, Yonsei University College of Medicine, Internal Medicine, Seoul, South Korea, 2Korea University College of Medicine, Preventive Medicine, Seoul, South Korea, 3Gangnam Severance Hospital, Yonsei University College of Medicine, Obstetrics and Gynaecology, Seoul, South Korea
P216
Natural course of inflammatory bowel disease in a Turkish cohort: a single tertiary centre experience in Ankara (2006–2015)
I. Yuksel*1, 2, Y. Coskun1, H. Akinci1, M. Hamamci1, E. Erarslan1, Y. Ustun1, Z. Simsek1, S. Coban1
1Diskapi Yildirim Beyazit Education and Research Hospital, Gastroenterology, Ankara, Turkey, 2Yildirim Beyazit University School of Medicine, Gastroenterology, Ankara, Turkey
P217
Risk factors of primary sclerosing cholangitis and cirrhosis in ulcerative colitis
Z. Azizi*1, Y. Farbod2, S. Javid2, N. Ebrahimi Daryani2, V. Basirat2
1Iran University of medical sciences, Tehran, Iran, Islamic Republic of, 2Tehran university of medical sciences, Tehran, Iran, Islamic Republic of
P218
Oral manifestations in inflammatory bowel disease patients under anti-tumour necrosis factor treatment
M. Barreiro-de Acosta*1, P. Rio2, R. Ferreiro1, M. J. Bouza1, M. d. C. Pombo1, A. Lorenzo1, M. Gallas2, J. E. Dominguez-Munoz1
1University Hospital Santiago de Compostela, Gastroenterology, Santiago, Spain, 2Odontology University, Santiago, Spain
P219
Accuracy of imaging for the preoperative measurement of the ileocolonic Crohn’s disease length: results of a prospective cohort study
A. Brouquet*1, A.-S. Rangheard2, J. Ifergan2, T. Lazure3, F. Carbonnel4, C. Penna1, S. Benoist1
1Bicêtre Hospital - Université Paris Sud, Oncologic and Digestive Surgery, Le Kremlin Bicêtre, France, 2Bicêtre Hospital - Université Paris Sud, Radiology, Le Kremlin Bicêtre, France, 3Bicêtre Hospital - Université Paris Sud, Pathology, Le Kremlin Bicêtre, France, 4Bicêtre Hospital - Université Paris Sud, Gastroenterology, Le Kremlin Bicêtre, France
P220
Total colonoscopy is needed to establish the diagnosis of lymphocytic colitis: results from a single-centre retrospective cohort
C. Csóka1, P. Miheller1, A. A. Csontos1, T. Micsik2, K. Hagymási1, L. Herszényi1, M. Juhász1, D. Lippai1, E. Mihály1, K. Müllner1, A. M. Németh1, Z. Péter1, F. Sipos1, H. Székely1, Z. Tulassay1, G. Valcz3, A. V. Patai*1
1Semmelweis University, Second Department of Medicine, Budapest, Hungary, 2Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary, 3Hungarian Academy of Sciences, Molecular Molecular Medicine Research Group, Budapest, Hungary
P221
Crohn’s disease activity evaluation based on imaging studies and biomarkers
G. Piotrowicz*1, J. Kowerzanow2, M. Kaszubowski3, E. Szurowska4, G. Rydzewska5
1Self-Dependet Health Care Unit of Ministry of Interior, Gastroenterology, Gdansk, Poland, 2Self-Dependent Health Care Unit of Ministry of Interior, Gastroenterology, Gdansk, Poland, 3Technical University of Gdansk, Economy, Gdansk, Poland, 4Medical University of Gdansk, Radiology, Gdansk, Poland, 5Central Clinical Hospital of the Ministry of Interior of Warsaw, Gastroenterology, Warsaw, Poland
P222
The onset of clinical manifestations in patients with inflammatory bowel disease
V. Nóbrega1, J. Silva1, B. Brito1, I. Silva1, M. C. Silva1, A. Pimentel2, F. Fortes2, B. C. da Silva*3, 4, N. Almeida2, N. Almeida2, V. Surlo2, J. Mota2, G. Santana1
1Universidade do Estado da Bahia, Medicine, Salvador, Brazil, 2Roberto Santos General Hospital, Gastroenterology, Salvador, Brazil, 3Federal University of Bahia, Gastroenterology, Salvador, Brazil, 4Hospital da Bahia, Gastroenterology, Salvador, Brazil
P223
Bowel damage in Crohn’s disease: direct comparison of ultrasonography– and magnetic resonance–based Lemann index
N. Imperatore*1, A. Rispo1, A. Testa1, P. Mainenti2, G. D. De Palma1, M. Rea1, O.M. Nardone1, G. Luglio1, P. Gervetti1, M. L. Taranto1, F. Castiglione1
1University ‘Federico II’ of Naples, Department of Clinical Medicine and Surgery, Naples, Italy, 2University ‘Federico II’ of Naples, Naples, Italy
P224
Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort: prevalence, risk factors, and long-term follow-up
M. Fraga*1, N. Fournier2, E. Safroneeva3, V. Pittet4, A. Nydegger5, S. Vavricka6, D. Moradpour1, A. Schoepfer1
1CHUV - Centre Hospitalier Universitaire Vaudois, Department of Gastroenterology and Hepatology, Lausanne, Switzerland, 2Institute for Social and Preventive Medicine, Healthcare Evaluation Unit, Lausanne, Switzerland, 3Institute of Social and Preventive Medicine, Division of Clinical Epidemiology and Biostatics, University of Bern, Bern, Switzerland, 4Institute For Social And Preventive Medicine, Health Care Evaluation Unit, Lausanne, Switzerland, 5Centre Hospitalier Universitaire Vaudois CHUV, Unité de Gastroentérologie / Nutrition pédiatrique, Lausanne, Switzerland, 6Stadtspital Triemli, Department of Gastroenterology and Hepatology, Zurich, Switzerland
P225
Cross-sectional evaluation of transmural healing in patients with Crohn’s disease on maintenance treatment with biologics
A. Testa*1, A. Rispo1, P. Mainenti2, N. Imperatore1, G. D. De Palma1, M. Rea1, F. Maione1, O. M. Nardone1, M. L. Taranto1, F. Castiglione1
1University ‘Federico II’ of Naples, Department of Clinical Medicine and Surgery, Naples, Italy, 2University ‘Federico II’ of Naples, Naples, Italy
P226
The first validated post-operative endoscopic Crohn’s disease index: the POCER index— identification of key endoscopic prognostic factors
P. De Cruz*1, 2, M. Kamm1, A. Hamilton2, K. Ritchie3, A. Gorelik2, D. Liew2, I. Lawrance4, J. Andrews5, P. Bampton6, P. Gibson7, M. Sparrow7, R. Leong8, T. Florin9, R. Gearry10, G. Radford-Smith9, F. Macrae2, H. Debinski11, W. Selby12, I. Kronborg1, M. Johnston13, R. Woods14, R. Elliott3, S. Bell3, S. Brown3, W. Connell3, P. Desmond3
1University of Melbourne, Gastroenterology, Melbourne, Australia, 2University of Melbourne, Medicine, Melbourne, Australia, 3St Vincent’s University Hospital, Department of Gastroenterology, Melbourne, Australia, 4University of Western Australia, Gastroenterology, Perth, Australia, 5University of Adelaide, Adelaide, Australia, 6Flinders University, Gastroenterology, Flinders, Australia, 7Monash University, Gastroenterology, Melbourne, Australia, 8University Of Sydney, Concord Repatriation General Hospital, Department of Gastroenterology, Sydney, Australia, 9Queensland Institute of Medical Research, Medicine, Brisbane, Australia, 10University of Otago, Christchurch, Department of IBD, Gastroenterology, Christchurch, New Zealand, 11Monash University, Medicine, Melbourne, Australia, 12University of New South Wales, Gastroenterology, Sydney, Australia, 13St Vincent’s University Hospital, Department of Colorectal Surgery, Melbourne, Australia, 14St Vincent’s University Hospital, Department of Colorectal Surgery, Melbourne, Australia, Melbourne, Australia
P227
Faecal calprotectin reductions in patients achieving mucosal healing with vedolizumab induction therapy in GEMINI 1
J. D. Lewis*1, W. Reinisch2, B. Bressler3, A. Parikh4, H. Yang5, M. Rosario5, A. Roseth6, S. Danese7, B. G. Feagan8, B. E. Sands9, P. Ginsburg10, T. Dassopoulos11, J. Xu5, T. Wyant5
1University of Pennsylvania Perelman School of Medicine, Gastroenterology, Philadelphia, Pennsylvania, United States, 2Univ. Klinik für Innere Medizin III, Vienna, Austria & McMaster University, Hamilton, Ontario, Canada, 3University of British Columbia, Vancouver, BC, Canada, 4Takeda Pharmaceuticals International, Inc, Deerfield, Illinois, United States, 5Takeda Pharmaceuticals International Co, Cambridge, Massachusetts, United States, 6Lovisenberg Diaconal Hospital, Oslo, Norway, 7IBD Centre, Istituto Clinico Humanitas, Milan, Italy, 8Robarts Research Institute, University of Western Ontario, Clinical Trials, London, Ontario, Canada, 9Icahn School of Medicine at Mount Sinai Hospital, New York, New York, United States, 10Gastroenterology Centre of Connecticut, Hamden, Connecticut, United States, 11Gastroenterology Division, Washington University School of Medicine, St. Louis, Missouri, United States
P228
Prevalence of malnutrition and nutritional characteristics of patients with inflammatory bowel disease
M. Casanova*1, M. Chaparro1, B. Molina2, O. Merino3, O. Nuevo-Siguairo4, C. Dueñas-Sadornil5, A.M. García-Albert6, D. Hervías7, X. Calvet8, L. Bujanda9, G.E. Rodríguez10, M. Montoro11, L. Castro-Laria12, M. Barreiro-de Acosta13, M. Van Domselaar14, J. M. Huguet15, P. Ramírez de la Piscina16, J. Barrio17, A. Algaba18, A. D. Ávila19, S. Torra20, L. Pozzati21, F. J. Martínez-Cerezo22, M. Calvo23, M. Charro24, P. López-Serrano25, M. R. Arribas-López26, M. Muñoz Vicente27, M. L. Rincón28, A. C. Peláez29, E. Castro30, A. García-Herola31, R. Batanero32, A. Castaño-García33, P. Robledo-Andrés34, M. B. Gómez-Sánchez35, A. Figuerola36, J. M. Banales37, L. Díaz-Hernández10, I. Vázquez38, F. Arguelles-Arias12, E. Marti-Bonmati39, F. Bermejo18, P. Serrano40, I. Megias-Rangil41, M. Campderá42, A. Barragán43, A. Merchante44, J. P. Gisbert1
1Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 2Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Endocrinology Unit, Madrid, Spain, 3Hospital Universitario de Cruces, Gastroenterology Unit, Bilbao, Spain, 4Hospital Central de Asturias, Gastroenterology unit, Oviedo, Spain, 5Hospital San Pedro de Alcántara, Gastroenterology Unit, Cáceres, Spain, 6Hospital Universitario Reina Sofía, Gastroenterology Unit, Murcia, Spain, 7Hospital Virgen de la Altagracia, Gastroenterology Unit, Manzanares, Spain, 8Corporació Sanitària Parc Taulí and CIBERehd, Gastroenterology Unit, Sabadell, Spain, 9Hospital de Donostia, Instituto Biodonostia, UPV/EHU and CIBEREHD, Gastroenterology Unit, Guipuzcoa, Spain, 10Hospital Universitario Nuestra Señora de La Candelaria, Gastroenterology Unit, Tenerife, Spain, 11Hospital San Jorge, Gastroenterology Unit, Huesca, Spain, 12Hospital Universitario Virgen de La Macarena, Gastroenterology Unit, Sevilla, Spain, 13Hospital Clínico Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 14Hospital de Torrejón, Gastroenterology Unit, Madrid, Spain, 15Consorcio Hospital General Universitario de Valencia, Gastroenterology Unit, Valencia, Spain, 16Hospital Universitario de Alava, Gastroenterology Unit, Vitoria, Spain, 17Hospital Universitario Rio Hortega, Gastroenterology Unit, Valladolid, Spain, 18Hospital Universitario de Fuenlabrada, Gastroenterology Unit, Madrid, Spain, 19Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain, 20Parc Sanitari Sant Joan de Déu, Gastroenterology Unit, Barcelona, Spain, 21Hospital de Mérida, Gastroenterology Unit, Mérida, Spain, 22Hospital Universitario Sant Joan de Reus, Gastroenterology Unit, Tarragona, Spain, 23Hospital Universitario Puerta de Hierro, Gastroenterology Unit, Madrid, Spain, 24Hospital Royo Villanova, Gastroenterology Unit, Zaragoza, Spain, 25Hospital Universitario Fundación Alcorcón, Gastroenterology Unit, Madrid, Spain, 26Hospital Universitario Infanta Sofía, Gastroenterology Unit, Madrid, Spain, 27Hospital General Universitario de Castellón, Gastroenterology Unit, Castellón, Spain, 28Hospital Comarcal Bidasoa, Gastroenterology Unit, Guipúzkoa, Spain, 29Hospital General de Catalunya, Gastroenterology Unit, Barcelona, Spain, 30Hospital Lucus Augusti, Gastroenterology Unit, Lugo, Spain, 31Hospital Marina Baixa, Gastroenterology Unit, Alicante, Spain, 32Hospital Universitario de Cruces, Endocrinology Unit, Bilbao, Spain, 33Hospital Central de Asturias, Gastroenterology Unit, Oviedo, Spain, 34Hospital Universitario San Pedro Alcántara, Gastroenterology Unit, Cáceres, Spain, 35Hospital Universitario Reina Sofía, Endocrinology Unit, Murcia, Spain, 36Hospital de Sabadell. Institut Universitari ParcTaulí and CIBERehd, Gastroenterology Unit, Sabadell, Spain, 37Hospital de Donostia, Endocrinology Unit, Donostia, Spain, 38Hospital San Jorge, Endocrinology Unit, Huesca, Spain, 39Hospital General Universitario de Valencia, Pharmacy Unit, Valencia, Spain, 40Hospital Universitario Virgen del Rocío, Endocrinology Unit, Sevilla, Spain, 41Hospital Universitario Sant Joan de Reus, Endocrinology Unit, Tarragona, Spain, 42Hospital Universitario Puerta de Hierro, Endocrinology Unit, Madrid, Spain, 43Hospital Royo Villanova, Endocrinology Unit, Zaragoza, Spain, 44Hospital General Universitario de Castellón, Endocrinology Unit, Castellón, Spain
P229
Evidence of content validity and psychometric properties of SF-36 for measuring health-related quality of life of patients with Crohn’s disease
A. Yarlas1, M. White1, M. Ingham2, D. Naessens*3, C. Han3
1Optum, Lincoln, Nebraska, United States, 2Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, United States, 3Janssen Pharmaceutica NV, Beerse, Belgium
P230
Elevated angiopoietins independent of TNF α regulation appear to play a key role in immune mediated angiogenesis in inflammatory bowel disease
M. Hussey*1, G. Holleran1, K. Grooteman2, S. Smith3, D. McNamara1
1Adelaide and Meath Hospital, Trinity College Dublin, Gastroenterology, Trinity Academic Gastroenterology Group, Dublin, Ireland, 2Radboud University Medical Centre, Department of Gastroenterology, Nijmegen, Netherlands, 3Trinity College Dublin, Clinical Medicine, Trinity Academic Gastroenterology Group, Dublin, Ireland